09.30 | 6.30 – Regulatory Guidance for Liquid Biopsy Applications in Clinical Programs
Time: 9:30 am
day: Day Three
Details:
- Data assembly considerations for regulatory review
- Regulatory considerations for varying LBx applications and profiling technologies
- Endpoint considerations in clinical trial design
- Establishing ctDNA changes as a surrogate marker in the metastatic and adjuvant settings
